Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.4% - Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price traded down 4.4% during trading on Wednesday . The company traded as low as $7.04 and last traded at $7.16. 4,653,415 shares traded hands during trading, a decline of 70% from the average session volume of 15,549,441 shares. The stock had previously closed at $7.49.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Needham & Company LLC reiterated a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. KeyCorp reduced their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $8.75.

Recursion Pharmaceuticals Price Performance

The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of -4.75 and a beta of 0.85. The stock's 50 day moving average price is $6.91 and its two-hundred day moving average price is $7.02.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same period last year, the company posted ($0.43) earnings per share. The company's revenue was up 147.6% compared to the same quarter last year. Analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares of the company's stock, valued at $11,487,173.46. This represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the firm's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total value of $76,351.49. Following the completion of the sale, the director now directly owns 7,089,007 shares in the company, valued at approximately $47,283,676.69. This represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 55,341 shares of company stock valued at $393,490. 15.75% of the stock is owned by insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its stake in shares of Recursion Pharmaceuticals by 20.3% in the second quarter. Bank of New York Mellon Corp now owns 1,060,804 shares of the company's stock valued at $7,956,000 after buying an additional 178,994 shares during the period. Commonwealth Equity Services LLC lifted its stake in Recursion Pharmaceuticals by 25.7% during the second quarter. Commonwealth Equity Services LLC now owns 44,241 shares of the company's stock worth $332,000 after purchasing an additional 9,058 shares during the period. Rhumbline Advisers lifted its stake in Recursion Pharmaceuticals by 24.1% during the second quarter. Rhumbline Advisers now owns 281,348 shares of the company's stock worth $2,110,000 after purchasing an additional 54,576 shares during the period. Victory Capital Management Inc. lifted its stake in Recursion Pharmaceuticals by 13.5% during the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company's stock worth $164,000 after purchasing an additional 2,598 shares during the period. Finally, Arizona State Retirement System lifted its stake in Recursion Pharmaceuticals by 11.1% during the second quarter. Arizona State Retirement System now owns 47,691 shares of the company's stock worth $358,000 after purchasing an additional 4,760 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.